Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cecily Quinn

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expressionNehal M Atallah, Maria Haque, Cecily Quinn, et al.
The Lancet. Oncology|October 25, 2020
How current assay approval policies are leading to unintended imprecision medicineRoberto Salgado, Andrew M Bellizzi, David Rimm, et al.
Pathology Oncology Research : POR|April 10, 2017
Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?Gábor Cserni, Tamás Zombori, Xavier Andreu, et al.
The Breast Journal|June 15, 2019
False-negative rate of ultrasound-guided fine-needle aspiration cytology for identifying axillary lymph node metastasis in breast cancer patientsGavin Kane, Christina Fleming, Helen Heneghan, et al.
Irish Journal of Medical Science|May 17, 2018
Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancerMegan Greally, Jennifer Kielty, Geoffrey A Watson, et al.
Journal of Clinical Pathology|August 12, 2016
Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breastKalnisha Naidoo, Brooke Beardsley, Pauline J Carder, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
British Journal of Cancer|February 18, 2021
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negativePaolo Giorgi Rossi, Annette Lebeau, Carlos Canelo-Aybar, et al.
Histopathology|October 22, 2013
Investigation of molecular alterations of AKT-3 in triple-negative breast cancerGillian O'Hurley, Etáin Daly, Anthony O'Grady, et al.
British Journal of Cancer|May 19, 2018
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" projectGiuseppe Gullo, Naomi Walsh, David Fennelly, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expressionNehal M Atallah, Maria Haque, Cecily Quinn, et al.
The Lancet. Oncology|October 25, 2020
How current assay approval policies are leading to unintended imprecision medicineRoberto Salgado, Andrew M Bellizzi, David Rimm, et al.
Pathology Oncology Research : POR|April 10, 2017
Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?Gábor Cserni, Tamás Zombori, Xavier Andreu, et al.
The Breast Journal|June 15, 2019
False-negative rate of ultrasound-guided fine-needle aspiration cytology for identifying axillary lymph node metastasis in breast cancer patientsGavin Kane, Christina Fleming, Helen Heneghan, et al.
Irish Journal of Medical Science|May 17, 2018
Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancerMegan Greally, Jennifer Kielty, Geoffrey A Watson, et al.
Journal of Clinical Pathology|August 12, 2016
Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breastKalnisha Naidoo, Brooke Beardsley, Pauline J Carder, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
British Journal of Cancer|February 18, 2021
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negativePaolo Giorgi Rossi, Annette Lebeau, Carlos Canelo-Aybar, et al.
Histopathology|October 22, 2013
Investigation of molecular alterations of AKT-3 in triple-negative breast cancerGillian O'Hurley, Etáin Daly, Anthony O'Grady, et al.
British Journal of Cancer|May 19, 2018
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" projectGiuseppe Gullo, Naomi Walsh, David Fennelly, et al.
Pageof 7